Investor presentation

RNS Number : 8472L

Shield Therapeutics PLC

15 January 2021

 

Shield Therapeutics plc

("Shield" or the "Group" or the "Company")

Investor presentation

London, UK, 15 January 2021:  Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces it will present at the Shares and AJ Bell Investor Evening Webinar, providing an overview of the business and progress being made by the Company.

Tim Watts, Chief Executive Officer, will present online at the Shares Spotlight webinar on Wednesday 20 January 2021. The event starts at 18.00 and Tim will be presenting at 18.55. Investors can register to attend here: https://bit.ly/3sjqqiI  

No new material information will be disclosed at the event and the presentation will be made available on the Company website shortly after the events here: https://www.shieldtherapeutics.com/investors/presentations .  

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Tim Watts, CEO	[phone]
Lucy Huntington-Bailey, Company Secretary and General Counsel	[phone]
Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden	[phone]
Joint Broker finnCap Ltd  Geoff Nash/Matt Radley/Alice Lane	[phone]
Financial PR & IR Advisor
Walbrook PR	[phone] or  [e-mail]
Paul McManus/Lianne Cawthorne	[phone] / [phone]

About Shield Therapeutics plc

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel,  non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the UK and European Union by Norgine B.V. and the Company is currently in the process of evaluating commercialisation options for the US market, including the potential launch of Accrufer ® in the US by Shield. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

 

END

 

 

NRABAMLTMTIBMRB